Literature DB >> 32520837

Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis.

Eugene Lin1,2,3,4, Glenn M Chertow5,6, Jay Bhattacharya7, Darius Lakdawalla2,4,8.   

Abstract

BACKGROUND: Uninsured patients with end-stage renal disease face barriers to peritoneal dialysis (PD), a type of home dialysis that is associated with improved quality of life and reduced Medicare costs. Although uninsured patients using PD at dialysis start receive retroactive Medicare coverage for required predialysis services, coverage only applies for the calendar month of dialysis start. Thus, initiating dialysis later in the month yields longer retroactive coverage.
OBJECTIVES: To examine whether differences in retroactive Medicare were associated with decreased long-term PD use. RESEARCH
DESIGN: We exploited the dialysis start date using a regression discontinuity design on a national cohort from the US Renal Data System.
SUBJECTS: 36,256 uninsured adults starting dialysis between January 1, 2006 and December 31, 2014. MEASURES: PD use at dialysis days 1, 90, 180, and 360.
RESULTS: Starting dialysis on the first versus last day of the calendar month was associated with an absolute decrease in PD use of 2.7% [95% confidence interval (CI), 1.5%-3.9%], or a relative decrease of 20% (95% CI, 12%-27%) at dialysis day 360. The absolute decrease was 5.5% (95% CI, 3.5%-7.2%) after Medicare established provider incentives for PD in 2011 and 7.2% (95% CI, 2.5%-11.9%) after Medicaid expansion in 2014. Patients were unlikely to switch from hemodialysis to PD after the first month of dialysis (probability of 6.9% in month 1, 1.5% in month 2, and 0.9% in month 4).
CONCLUSIONS: Extending retroactive coverage for preparatory dialysis services could increase PD use and reduce overall Medicare spending in the uninsured.

Entities:  

Mesh:

Year:  2020        PMID: 32520837      PMCID: PMC7295012          DOI: 10.1097/MLR.0000000000001350

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  31 in total

1.  A Randomized Controlled Trial to Determine the Appropriate Time to Initiate Peritoneal Dialysis after Insertion of Catheter (Timely PD Study).

Authors:  Dwarakanathan Ranganathan; George T John; Edward Yeoh; Nicola Williams; Barry O'Loughlin; Thin Han; Lakshmanan Jeyaseelan; Kavitha Ramanathan; Helen Healy
Journal:  Perit Dial Int       Date:  2017-04-13       Impact factor: 1.756

2.  Systematic barriers to the effective delivery of home dialysis in the United States: a report from the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis.

Authors:  Thomas A Golper; Anjali B Saxena; Beth Piraino; Isaac Teitelbaum; John Burkart; Fredric O Finkelstein; Ali Abu-Alfa
Journal:  Am J Kidney Dis       Date:  2011-09-08       Impact factor: 8.860

3.  Health Insurance and the Use of Peritoneal Dialysis in the United States.

Authors:  Jose J Perez; Bo Zhao; Samaya Qureshi; Wolfgang C Winkelmayer; Kevin F Erickson
Journal:  Am J Kidney Dis       Date:  2017-12-23       Impact factor: 8.860

4.  Association of Medicaid Expansion With 1-Year Mortality Among Patients With End-Stage Renal Disease.

Authors:  Shailender Swaminathan; Benjamin D Sommers; Rebecca Thorsness; Rajnish Mehrotra; Yoojin Lee; Amal N Trivedi
Journal:  JAMA       Date:  2018-12-04       Impact factor: 56.272

5.  Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme.

Authors:  T L Griffiths; C J Phillips; S Davies; M L Burr; I A Campbell
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

Review 6.  How to overcome barriers and establish a successful home HD program.

Authors:  Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

7.  Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments To Correct Existing Regulations Related to the CBP for Certain DMEPOS. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2018-11-14

8.  Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis.

Authors:  Haya R Rubin; Nancy E Fink; Laura C Plantinga; John H Sadler; Alan S Kliger; Neil R Powe
Journal:  JAMA       Date:  2004-02-11       Impact factor: 56.272

Review 9.  An integrated review of "unplanned" dialysis initiation: reframing the terminology to "suboptimal" initiation.

Authors:  David C Mendelssohn; Christine Malmberg; Bassem Hamandi
Journal:  BMC Nephrol       Date:  2009-08-12       Impact factor: 2.388

10.  Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM).

Authors:  Fang Fang Jiao; Colman Siu Cheung Fung; Eric Yuk Fai Wan; Anca Ka Chun Chan; Sarah Morag McGhee; Ruby Lai Ping Kwok; Cindy Lo Kuen Lam
Journal:  Diabetes Care       Date:  2017-12-15       Impact factor: 19.112

View more
  3 in total

1.  The "Advancing American Kidney Health" Executive Order: Challenges and Opportunities for the Large Dialysis Organizations.

Authors:  Eugene Lin; Paul B Ginsburg; Glenn M Chertow; Jeffrey S Berns
Journal:  Am J Kidney Dis       Date:  2020-08-05       Impact factor: 8.860

2.  Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis.

Authors:  Eugene Lin; Khristina I Lung; Glenn M Chertow; Jay Bhattacharya; Darius Lakdawalla
Journal:  Value Health       Date:  2021-07-30       Impact factor: 5.101

3.  The COVID-19 Pandemic Converges With Kidney Policy Transformation: Implications for CKD Population Health.

Authors:  Sri Lekha Tummalapalli; Neil Warnock; Mallika L Mendu
Journal:  Am J Kidney Dis       Date:  2020-11-07       Impact factor: 8.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.